Oncology Clinical Trials

  1. Sudocetaxel zendusortide is in early phase development in cancer patients with advanced solid tumors. The FDA has granted a Fast-Track development program for the investigation of sudocetaxel zendusortide as a single agent, for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
  2. Sudocetaxel zendusortide-CTR-0001 (ClinicalTrials.gov Identifier: NCT04706962) is an open label first in human (FIH) study of sudocetaxel zendusortide in solid cancers.